Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Payables (2016 - 2025)

Marimed (MRMD) has disclosed Payables for 15 consecutive years, with $13.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables fell 21.84% to $13.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.6 million, a 21.84% decrease, with the full-year FY2024 number at $18.3 million, up 88.35% from a year prior.
  • Payables was $13.6 million for Q3 2025 at Marimed, up from $11.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $18.8 million in Q1 2025 to a low of $4.7 million in Q1 2023.
  • A 5-year average of $10.2 million and a median of $8.7 million in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: tumbled 75.91% in 2021, then skyrocketed 141.63% in 2024.
  • Marimed's Payables stood at $6.5 million in 2021, then surged by 59.78% to $10.4 million in 2022, then decreased by 6.5% to $9.7 million in 2023, then surged by 88.35% to $18.3 million in 2024, then decreased by 25.94% to $13.6 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Payables are $13.6 million (Q3 2025), $11.2 million (Q2 2025), and $18.8 million (Q1 2025).